Glucagon-like peptide-1 analog: Difference between revisions

Revision as of 23:13, 6 March 2009

Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes.^[1]

One of their advantages is that they have a lower risk of causing hypoglycemia.

Licenced : exenatide (2005)

↑ http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide"

v t e Oral antidiabetic drugs and Insulin analogs (A10)
Biguanides	Metformin
Sulfonylureas	Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide
Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose
Thiazolidinediones (TZD)	Pioglitazone, Rivoglitazone^†, Rosiglitazone, Troglitazone^‡
Meglitinides	Nateglinide, Repaglinide, Mitiglinide
Dipeptidyl peptidase-4 (DPP-4) inhibitors	Alogliptin^†, Saxagliptin^†, Sitagliptin, Vildagliptin, Linagliptin^†
Glucagon-like peptide-1 analog	Exenatide, Liraglutide^†, Albiglutide^†
Amylin analog	Pramlintide
Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir)
Dual PPAR agonists	Aleglitazar^†, Muraglitazar^§, Tesaglitazar^§
SGLT2 inhibitor	Dapagliflozin^†, Remogliflozin^†
^†Undergoing clinical trials. ^‡ Withdrawn from market. ^§Development halted.